Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

European Research Council grant · Running

DynamITE Modulating Drug Transporters Dynamics to Improve Therapeutic Efficacy

Coordinator
Universite Libre De Bruxelles, Belgium
Runs
1 January 2026 to 31 December 2030
Status
Running
EU funding
€1.7m
Total cost
€1.7m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101221822

What the project is doing

In the project's own words, from its summary on CORDIS.

The therapeutic effect of a drug is largely determined by how effectively it reaches its site of action. Drug distribution in the human body is defined by an intricate network of transporters, offering potential for dynamically controlling where a drug spends most of its time. DynamITE aims to provide the tools to manipulate this ""highway network"" of drug transport at will. DynamITE will exploit the common mechanism shared by transporters, that is the alternating-access.

Every transporter must dynamically switch between different states to enable directional transport of its substrate through the biological membrane. At the molecular level, this involves important local and global changes in the protein's three-dimensional structure. The foundational methodology of DynamITE is a structural mass spectrometry approach that reports on such changes: hydrogen-deuterium exchange coupled to mass spectrometry (HDX-MS).

I have demonstrated that HDX-MS can fingerprint the effects of drugs on the dynamic switching between states. DynamITE builds on this knowledge to identify and design modulators of transporter dynamics. A modulator that prevents the conformational changes underlying transport will block drug transport, while a modulator that increases the rate of conformational transitions will accelerate transport. DynamITE’s approach will be applied to selected drug transporters with proven critical roles in antibiotic resistance, drug toxicity, and drug transport into the brain.

In parallel, DynamITE will advance the HDX-MS technique to make it applicable to living cells. Such a development will enable the observation of protein dynamics in cellulo, with a molecular level of resolution—something currently inaccessible. This methodological breakthrough be used to monitor drug transporters dynamics while in action within the cell. The toolbox developed within DynamITE will be applicable to any transporter for which targeted modulation of transport activity is desired. ""

Topics

Who is involved

OrganisationCityCountryRole
Universite Libre De BruxellesBruxellesBelgiumCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI